Hepatitis C

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.

Management of HCV in Liver Transplant Candidates and Recipients

Management of HCV in Liver Transplant Candidates and Recipients

By

Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

By

The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.

Screening for Viral Hepatitis Recommended Before Biologics in RA

Screening for Viral Hepatitis Recommended Before Biologics in RA

By

The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.

 Knowledge of HCV Transmission in Opioid-Dependent Pregnant Women

Knowledge of HCV Transmission in Opioid-Dependent Pregnant Women

By

Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of hepatitis C virus.

 High Rate of SVR Across All HCV Genotypes With Three-Drug Combo

High Rate of SVR Across All HCV Genotypes With Three-Drug Combo

A combination pill of sofosbuvir, velpatasvir, and voxilaprevir is nearly 100% effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents.

Novel RNA Virus Detected With Next-Generation Metagenomic Sequencing

Novel RNA Virus Detected With Next-Generation Metagenomic Sequencing

Next-generation metagenomic sequencing can detect a new RNA virus, human hepegivirus-1.

Hepatitis C Virus Infection: A Risk Factor for Type 2 Diabetes?

Hepatitis C Virus Infection: A Risk Factor for Type 2 Diabetes?

By

Hepatitis C virus infection may increase the risk for type 2 diabetes, but whether a causal relationship exists is unclear. Screening for type 2 diabetes in this population may have important public health implications.

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.

Transplantation of HCV-Infected Kidneys Into Uninfected Patients Possible

Transplantation of HCV-Infected Kidneys Into Uninfected Patients Possible

Researchers evaluated the safety and efficacy of transplantation of kidneys from HCV genotype 1-viremic donors into HCV-negative patients, followed by elbasvir-grazoprevir (Zepatier) treatment.

Sharp Increase in Maternal HCV Infection in US

Sharp Increase in Maternal HCV Infection in US

Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.

CDC: Rise in HCV Infections Tripled in Last 5 Years

CDC: Rise in HCV Infections Tripled in Last 5 Years

The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.

Congressional Acts Pose Threat to National ID Health Initiatives

Congressional Acts Pose Threat to National ID Health Initiatives

By

Passage of the 2017 budget, along with congressional approval of the AHCA, leaves large holes in the funding of the proposed national approach to infectious disease control.

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

By

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

By

Findings from the EXPEDITION-1 study, a phase 3 trial, evaluated the efficacy and safety of glecaprevir/pibrentasvir for the treatment of chronic HCV infection in patients with genotype 1, 2, 4, 5, or 6 and compensated cirrhosis.

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

By

Investigational dosage of once-daily ledipasvir/sofosbuvir was safe and highly efficacious in children age 6 to 11 with chronic HCV infection.

Clinical Practice Update on Managing Patients Cured of HCV Infection

Clinical Practice Update on Managing Patients Cured of HCV Infection

By

Patients with chronic HCV infection who have achieved a sustained virologic response with treatment are considered cured, but they may still be at risk for complications such as hepatocellular carcinoma. The American Gastroenterological Association Institute addresses these issues in its clinical practice update on managing patients cured of HCV infection.

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

By

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

By

While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

Despite being the seventh leading cause of death in the world, viral hepatitis accounts for less than 1% of the National Institutes of Health research budget.

Pharmacist Interventions Can Help to Optimize HCV Treatment

Pharmacist Interventions Can Help to Optimize HCV Treatment

By

Clinical pharmacists can encourage preventive measures on reducing HCV transmission, increase education adherence, assist in initiating HCV treatment, assist in monitoring clinical and adverse effects, and facilitate medication acquisition.

FDA Approves First HCV Drugs for Children and Adolescents

FDA Approves First HCV Drugs for Children and Adolescents

By

Harvoni (ledipasvir and sofosbuvir) has been approved for children with HCV genotype 1, 4, 5, or 6 infection. Sovaldi (sofosbuvir) has been approved for children with HCV genotype 2 or 3 infection, in combination with ribavirin.

HCV Infection May Increase Risk for Cataract Formation

HCV Infection May Increase Risk for Cataract Formation

By

HCV infection is associated with an increased risk for cataract formation, possibly due to HCV-related oxidative stress. Some treatment regimens, such as interferon/ribavirin combination therapy, also increase the risk for cataracts.

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Hepatitis B virus reactivation may occur in patients with chronic hepatitis C with current HBV infection treated with direct-acting antivirals.

Multiple DAA Regimens Safe, Efficacious for Treating HCV Genotype 1

Multiple DAA Regimens Safe, Efficacious for Treating HCV Genotype 1

Several direct-acting antiviral regimens were shown to be safe, tolerable, and efficient in treating hepatitis C virus genotype 1 infection.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA Expands Indication, Adds Boxed Warning for HCV Drug

By

FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.

Low Rates of HCV Testing Seen in Baby Boomers

Low Rates of HCV Testing Seen in Baby Boomers

Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.

Sign Up for Free e-newsletters